Danilo D’Alessandro is the Chief Financial Officer at ClearPoint Neuro, Inc., a leading medical device company specializing in precision neuro-navigation solutions for drug delivery, cell and gene therapy, and biopsy procedures. With more than 25 years of finance leadership experience in the medical device and healthcare sectors, Danilo plays a pivotal role in steering the company’s financial strategy, ensuring sustainable growth, and supporting its mission to transform neurological treatments. Before joining ClearPoint Neuro in 2023, Danilo served as CFO at Surmodics, Inc., where he orchestrated key financial initiatives, including mergers and acquisitions that expanded the company’s market reach and boosted shareholder value. His prior roles include Vice President of Finance at Boston Scientific Corporation, where he managed global financial operations for high-growth divisions, and senior finance positions at Integra LifeSciences Holdings Corporation, focusing on budgeting, forecasting, and capital markets activities. Danilo’s track record includes driving operational efficiencies, securing funding for innovative R&D, and navigating complex regulatory environments. In his current position at ClearPoint Neuro, Danilo oversees all financial functions, including investor relations, treasury management, and strategic planning. He has been instrumental in optimizing the company’s capital structure, enhancing cash flow management, and positioning ClearPoint for expansion in the burgeoning cell and gene therapy markets, contributing to significant milestones in revenue growth and platform commercialization.